Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | RP2 |
| Synonyms | |
| Therapy Description |
RP2 is an oncolytic virus engineered to express granulocyte-macrophage colony-stimulating factor (GM-CSF) and an antibody-like molecule targeted against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), which may lead to activation of anti-tumor immune response and tumor cell killing (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| RP2 | RP-2|RP 2 | RP2 is an oncolytic virus engineered to express granulocyte-macrophage colony-stimulating factor (GM-CSF) and an antibody-like molecule targeted against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), which may lead to activation of anti-tumor immune response and tumor cell killing (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04336241 | Phase I | Nivolumab + RP2 RP2 | Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors | Recruiting | GBR | ESP | 0 |